nach oben

memo - Magazine of European Medical Oncology

Tipp

New targeted therapies in kidney cancer

verfasst von: Karl Mayrhofer, MD, Dora Niedersüß-Beke, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Summary

New agents and combinations continue to change the clinical practice of treating patients with renal cell carcinoma. In this review we want to highlight the most recent therapeutic developments and also give an overview of the current standard of care in advanced disease. Studies investigating lenvatinib plus pembrolizumab, belzutifan and cabozantinib are discussed.

Vorheriger Artikel Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer

Nächster Artikel Tracking mutation and drug-driven alterations of oncokinase conformations

Motzer R, Alekseev B, Rha S‑Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300. CrossRef

Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. CrossRef

Bauer TM, Choueiri TK, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273. CrossRef

Srinivasan R, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(15_suppl):4555. CrossRef

Choueiri TK, Bauer TM, McDermott DF, Arrowsmith E, Roy A, Perini RF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(6_suppl):272. CrossRef

Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88. CrossRef

Song SH, Jeong IG, You D, Hong JH, Hong BS, Song C, et al. VEGF/VEGFR2 OR PDGF-β/PDGFR‑β expression in non-metastatic, renal cell carcinoma: a prospective study WiTH 1,091 consecutive cases. Int J Clin Exp Pathol. 2014;7:7681–9.

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45. CrossRef

Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. CrossRef

10.

ESMO. eUpdate—renal cell carcinoma treatment recommendations.. https://www.esmo.org/guidelines/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-recommendations-4. Accessed 2 Oct 2021.

11.

Lee C‑H, Voss MH, Carlo MI, Chen Y‑B, Reznik E, Knezevic A, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4509. CrossRef

12.

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. CrossRef

13.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. CrossRef

14.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. CrossRef

Titel: New targeted therapies in kidney cancer
verfasst von: Karl Mayrhofer, MD
Dora Niedersüß-Beke, MD, MBA
Publikationsdatum: 22.12.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00782-6

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

New targeted therapies in kidney cancer

Summary

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Cardiopulmonary sequelae of COVID-19

Tracking mutation and drug-driven alterations of oncokinase conformations

Antibody–drug conjugates—the magic bullet?

Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer

COVID-19: New disease mechanism is simultaneously a therapeutic target

Renal cell carcinoma—presentation highlights from the ESMO Congress 2021